Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. Thanks to global network, Sandoz medicines are now available to 90% of people worldwide. In addition to the direct cost savings to patients, Lek, a Sandoz company, contributes to the stability of healthcare systems worldwide and free up resources for new and innovative medicines.


Gorazd Hribar, PhD
Project manager nextBioPharmDSP

Phone: +386 1 7217699
Mobile: +386 41 830327


Karlsruhe Institute of Technology

"With more than 9,000 employees and an annual budget of about EUR 785 million, KIT is one of the biggest research and education institutions worldwide and has the potential of reaching a top position in selected research areas on an international level. The objective is to turn KIT into an institution of top research, excellent scientific education, and a prominent location of academic life, life-long learning, comprehensive advanced training, unrestricted exchange of know-how, and sustainable innovation culture."


Prof. Dr. Jürgen Hubbuch
Phone: +49 721 608 47526



Millipore S.A.S (France)
a subsidiary of Merck KGaA, Darmstadt, Germany

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.


Jean-Jacques Undereiner
Phone : +33 3 90 46 98 85



National Institute of Chemistry Slovenia

Basic and applied research oriented towards fields which are of long-term importance to both Slovenia and the world: biotechnology, environmental protection, structural and theoretical chemistry, analytical chemistry, materials research, and chemical engineering, through which the institute is in line with the needs of the domestic chemical, pharmaceutical, tire, and food industries. The work of the Institute is also in line with the priority thematic areas of the EU Research and Innovation programme Horizon 2020.

Two research groups from National Institute of Chemistry jointly work as a partner within this project:

  • Laboratory for Molecular Biology and Nanobiotechnology
  • Laboratory of Catalysis and Chemical Reaction Engineering


Simon Caserman, PhD
Phone: +386 1 4760 428



National Systems

National SYSTEMS is a company based in Italy specialized in technical – scientific support to SMEs for the development of new products using a wide range of cutting edge technologies.
National SYSTEMS co-operates with SMEs to realize their projects through an interdisciplinary support; our organization allows us to offer the highest level of support, in total security and at a very competitive costs.

Business Area

We are operative in Pharmaceuticals (micro-fluidic devices for real-time control of contaminants), Nano-Materials and graphene applications (industrial use of graphene and other new-generation materials), Life Sciences (miniaturized sensors for monitoring physiological parameters), Food Packaging (control contaminants in packaging) and Anti-Counterfeiting systems based on nanomaterials emission spectra (coding and marking products for pharmaceutical applications, food, automotive, fashion), industrial packaging and glass (defect inspection systems for customised applications).


Sergio Chiodini, PhD

Phone: +39 0331 988 425




Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees and its products are available in more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics.

In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).


Susanne Richter, PhD

Phone : +43 5372 69965380



University of Natural Resources and Life Sciences, Vienna

BOKU is a leading expert for renewable energy, agriculture, environmental safety, food technology and biotechnology. With a history dating back to 1872 and currently over 1000 scientists and teachers and over 12000 students it is pushing the important technologies for the future. A record of over 2000 publications a year shows the expertise and motivation of scientists, teachers and students alike. The Department of Biotechnology and the Laboratory of Protein Technology and Downstream Processing are world leading in future technologies for bioprocessing. The Department of Biotechnology always focus on application oriented research enabled by basic research and therefore has tight connection to various companies to meet the demands of the future.


Prof. Alois Jungbauer

Phone: +43 1 47654 6226